NCT05538312View on ClinicalTrials.gov

A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

April 24, 2023

Study Completion Date

May 22, 2023

Conditions
Healthy
Interventions
DRUG

vepdegestrant

Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant

DRUG

Itraconazole

Participants will receive itraconazole by mouth once a day for 11 days in Period 2.

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Arvinas Estrogen Receptor, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT05538312 - A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults | Biotech Hunter | Biotech Hunter